Victory Capital Management Inc. Acquires 30,811 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Victory Capital Management Inc. raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 100.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,348 shares of the company's stock after purchasing an additional 30,811 shares during the period. Victory Capital Management Inc. owned 0.06% of Dyne Therapeutics worth $1,445,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after buying an additional 698 shares during the last quarter. KBC Group NV boosted its stake in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Virtue Capital Management LLC lifted its holdings in shares of Dyne Therapeutics by 4.4% during the 3rd quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock valued at $834,000 after buying an additional 981 shares during the period. Finally, Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $36,000. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded down $0.18 during trading on Friday, hitting $12.08. The stock had a trading volume of 2,328,438 shares, compared to its average volume of 1,342,879. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11. Dyne Therapeutics, Inc. has a one year low of $11.18 and a one year high of $47.45. The stock has a 50 day simple moving average of $13.60 and a 200 day simple moving average of $24.26.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 6,237 shares of company stock valued at $77,760. Corporate insiders own 20.77% of the company's stock.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of recent research reports. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Raymond James upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Baird R W upgraded Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Finally, JPMorgan Chase & Co. dropped their price target on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.